Albemarle vs Hexcel
ALB and HXL side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALB and HXL compare
Albemarle is the larger company, worth 1.8 times as much as Hexcel ($10.3B against $5.8B).
On earnings, Hexcel is cheaper: it trades at 34.3× trailing earnings, against 325× for Albemarle.
Albemarle grew revenue faster over the last twelve months (18.3% versus 7.6% for Hexcel).
Hexcel keeps more of each dollar of sales as profit, with a net margin of 8.5% compared with 3.8% at Albemarle.
Both pay dividends: Albemarle yields 1.9% and Hexcel 0.71%.
Albemarle scores higher on the StockData Score (16 against 14 for Hexcel), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALB | HXL |
|---|---|---|
| Size and price | ||
| Market cap | $10.3B | $5.8B |
| Share price | $87.67 | $76.42 |
| Change, 1 year | −23.9% | 10.6% |
| Change, 5 years | −67.1% | 43.5% |
| Beta (5Y) | 1.35 | 0.69 |
| Employees | 7,800 | 5,563 |
| StockData Score | ||
| Total score | 16 (better) | 14 |
| Valuation score | 4 (better) | 2 |
| Growth score | 3 | 3 |
| Performance score | 1 | 2 (better) |
| Health score | 4 | 4 |
| Dividend score | 4 (better) | 3 |
| Valuation | ||
| P/E | 325× | 34.3× (better) |
| P/S | 1.8× (better) | 2.9× |
| P/B | 1.0× (better) | 4.4× |
| EV/EBITDA | 12.1× (better) | 18.1× |
| P/FCF | 7.7× (better) | 27.6× |
| FCF yield | 13.0% (better) | 3.6% |
| Fair value | $118.50 | $68.15 |
| Margin of safety | 26.0% (better) | −12.1% |
| Growth | ||
| Revenue growth (TTM) | 18.3% (better) | 7.6% |
| Revenue growth, 5Y average | 10.4% (better) | 4.7% |
| Net income growth (TTM) | – | 149% |
| EPS growth (TTM) | – | 162% |
| Profitability | ||
| Gross margin | 23.8% | 25.2% (better) |
| Operating margin | 4.3% | 12.2% (better) |
| Net margin | 3.8% | 8.5% (better) |
| FCF margin | 22.7% (better) | 10.4% |
| Return on equity | 2.2% | 11.9% (better) |
| Return on invested capital | 1.1% | 8.8% (better) |
| Financial health | ||
| Debt / equity | 0.18 (better) | 0.71 |
| Net debt / EBITDA | 0.27 (better) | 2.33 |
| Interest coverage | – | 5.2× |
| Current ratio | 2.09 | 2.57 (better) |
| Altman Z-score | 2.19 | 4.95 (better) |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 1.9% (better) | 0.71% |
| Payout ratio | 85.0% | 31.4% |
| Years of dividend growth | 16 (better) | 3 |
| Dividend growth, 5Y average | 1.0% | 32.0% (better) |
| Buyback yield | – | 6.1% |
| Shareholder yield | 1.9% | 6.8% (better) |
| Ownership | ||
| Held by institutions | 98.3% | 114% |
| Held by insiders | 0.35% | 1.0% |
| Insider net buying, 12 months | −$7.4M | −$2.1M (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 10.5% | 7.1% |
Go deeper
- ALB stock overview
- ALB income statement
- ALB valuation and score
- HXL stock overview
- HXL income statement
- HXL valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.